Debevoise Advises J.P. Morgan as Financial Advisor to Salix Pharmaceuticals in its Sale to Valeant Pharmaceuticals For an Enterprise Value of $14.5 Billion

22 February 2015

Debevoise & Plimpton LLP is advising J.P. Morgan Securities Services (“J.P. Morgan”) as financial advisor to Salix Pharmaceuticals, Ltd. (“Salix”) in its definitive agreement with Valeant Pharmaceuticals International, Inc. (“Valeant”) under which Valeant will acquire all of the outstanding common stock of Salix for $158.00 per share in cash, or a total enterprise value of approximately $14.5 billion. The transaction was approved by the Boards of Directors of both companies.

J.P. Morgan Securities Services is a premier securities servicing provider that helps institutional investors, alternative asset managers, broker dealers and equity issuers optimize efficiency, mitigate risk and enhance revenue. With $18.8 trillion in assets under custody and $7.5 trillion in assets under administration, Securities Services leverages the firm’s global scale, leading technology and deep industry expertise to service investments around the world.

The Debevoise team is led by partner Andrew L. Bab and includes associates Danli Guo and Douglas M. Hirn.

Debevoise & Plimpton LLP is a premier law firm with market-leading practices, a global perspective and strong New York roots. The firm’s commercially savvy lawyers regularly lead strategic transactions and complex disputes for world-class clients.